Cargando…

Next-generation sequencing of 500 POI patients identified novel responsible monogenic and oligogenic variants

BACKGROUND: Premature ovarian insufficiency refers to the loss of ovarian function before 40 years of age. The etiology is heterogeneous, and genetic factors account for 20–25% of cases. However, how to transform genetic findings to clinical molecular diagnose remains a challenge. To identify potent...

Descripción completa

Detalles Bibliográficos
Autores principales: Luo, Wei, Ke, Hanni, Tang, Shuyan, Jiao, Xue, Li, Zhuqing, Zhao, Shidou, Zhang, Feng, Guo, Ting, Qin, Yingying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9930292/
https://www.ncbi.nlm.nih.gov/pubmed/36793102
http://dx.doi.org/10.1186/s13048-023-01104-6
_version_ 1784889020666347520
author Luo, Wei
Ke, Hanni
Tang, Shuyan
Jiao, Xue
Li, Zhuqing
Zhao, Shidou
Zhang, Feng
Guo, Ting
Qin, Yingying
author_facet Luo, Wei
Ke, Hanni
Tang, Shuyan
Jiao, Xue
Li, Zhuqing
Zhao, Shidou
Zhang, Feng
Guo, Ting
Qin, Yingying
author_sort Luo, Wei
collection PubMed
description BACKGROUND: Premature ovarian insufficiency refers to the loss of ovarian function before 40 years of age. The etiology is heterogeneous, and genetic factors account for 20–25% of cases. However, how to transform genetic findings to clinical molecular diagnose remains a challenge. To identify potential causative variations for POI, a next generation sequencing panel with 28 known causative genes of POI was designed, and a large cohort of 500 Chinese Han patients was screened directly. Pathogenic evaluation of the identified variants and the phenotype analysis were performed according to monogenic or oligogenic variants. RESULTS: A total of 14.4% (72/500) of the patients carried 61 pathogenic or likely pathogenic variants in 19 of the genes in the panel. Interestingly, 58 variants (95.1%, 58/61) were firstly identified in patients with POI. FOXL2 harbored the highest occurrence frequency (3.2%, 16/500), among whom presented with isolated ovarian insufficiency instead of blepharophimosis-ptosis-epicanthus inversus syndrome. Moreover, luciferase reporter assay confirmed variant p.R349G, which account for 2.6% of POI cases, impaired the transcriptional repressive effect of FOXL2 on CYP17A1. The novel compound heterozygous variants in NOBOX and MSH4 were confirmed by pedigree haplotype analysis, and digenic heterozygous variants in MSH4 and MSH5 were firstly identified. Furthermore, nine patients (1.8%, 9/500) with digenic or multigenic pathogenic variants presented with delayed menarche, early onset of POI and high prevalence of primary amenorrhea compared with those with monogenic variation(s). CONCLUSIONS: The genetic architecture of POI has been enriched through the targeted gene panel in a large cohort of patients with POI. Specific variants in pleiotropic genes may result in isolated POI rather than syndromic POI, whereas oligogenic defects might have cumulative deleterious effects on the severity of POI phenotype.
format Online
Article
Text
id pubmed-9930292
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-99302922023-02-16 Next-generation sequencing of 500 POI patients identified novel responsible monogenic and oligogenic variants Luo, Wei Ke, Hanni Tang, Shuyan Jiao, Xue Li, Zhuqing Zhao, Shidou Zhang, Feng Guo, Ting Qin, Yingying J Ovarian Res Research BACKGROUND: Premature ovarian insufficiency refers to the loss of ovarian function before 40 years of age. The etiology is heterogeneous, and genetic factors account for 20–25% of cases. However, how to transform genetic findings to clinical molecular diagnose remains a challenge. To identify potential causative variations for POI, a next generation sequencing panel with 28 known causative genes of POI was designed, and a large cohort of 500 Chinese Han patients was screened directly. Pathogenic evaluation of the identified variants and the phenotype analysis were performed according to monogenic or oligogenic variants. RESULTS: A total of 14.4% (72/500) of the patients carried 61 pathogenic or likely pathogenic variants in 19 of the genes in the panel. Interestingly, 58 variants (95.1%, 58/61) were firstly identified in patients with POI. FOXL2 harbored the highest occurrence frequency (3.2%, 16/500), among whom presented with isolated ovarian insufficiency instead of blepharophimosis-ptosis-epicanthus inversus syndrome. Moreover, luciferase reporter assay confirmed variant p.R349G, which account for 2.6% of POI cases, impaired the transcriptional repressive effect of FOXL2 on CYP17A1. The novel compound heterozygous variants in NOBOX and MSH4 were confirmed by pedigree haplotype analysis, and digenic heterozygous variants in MSH4 and MSH5 were firstly identified. Furthermore, nine patients (1.8%, 9/500) with digenic or multigenic pathogenic variants presented with delayed menarche, early onset of POI and high prevalence of primary amenorrhea compared with those with monogenic variation(s). CONCLUSIONS: The genetic architecture of POI has been enriched through the targeted gene panel in a large cohort of patients with POI. Specific variants in pleiotropic genes may result in isolated POI rather than syndromic POI, whereas oligogenic defects might have cumulative deleterious effects on the severity of POI phenotype. BioMed Central 2023-02-15 /pmc/articles/PMC9930292/ /pubmed/36793102 http://dx.doi.org/10.1186/s13048-023-01104-6 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Luo, Wei
Ke, Hanni
Tang, Shuyan
Jiao, Xue
Li, Zhuqing
Zhao, Shidou
Zhang, Feng
Guo, Ting
Qin, Yingying
Next-generation sequencing of 500 POI patients identified novel responsible monogenic and oligogenic variants
title Next-generation sequencing of 500 POI patients identified novel responsible monogenic and oligogenic variants
title_full Next-generation sequencing of 500 POI patients identified novel responsible monogenic and oligogenic variants
title_fullStr Next-generation sequencing of 500 POI patients identified novel responsible monogenic and oligogenic variants
title_full_unstemmed Next-generation sequencing of 500 POI patients identified novel responsible monogenic and oligogenic variants
title_short Next-generation sequencing of 500 POI patients identified novel responsible monogenic and oligogenic variants
title_sort next-generation sequencing of 500 poi patients identified novel responsible monogenic and oligogenic variants
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9930292/
https://www.ncbi.nlm.nih.gov/pubmed/36793102
http://dx.doi.org/10.1186/s13048-023-01104-6
work_keys_str_mv AT luowei nextgenerationsequencingof500poipatientsidentifiednovelresponsiblemonogenicandoligogenicvariants
AT kehanni nextgenerationsequencingof500poipatientsidentifiednovelresponsiblemonogenicandoligogenicvariants
AT tangshuyan nextgenerationsequencingof500poipatientsidentifiednovelresponsiblemonogenicandoligogenicvariants
AT jiaoxue nextgenerationsequencingof500poipatientsidentifiednovelresponsiblemonogenicandoligogenicvariants
AT lizhuqing nextgenerationsequencingof500poipatientsidentifiednovelresponsiblemonogenicandoligogenicvariants
AT zhaoshidou nextgenerationsequencingof500poipatientsidentifiednovelresponsiblemonogenicandoligogenicvariants
AT zhangfeng nextgenerationsequencingof500poipatientsidentifiednovelresponsiblemonogenicandoligogenicvariants
AT guoting nextgenerationsequencingof500poipatientsidentifiednovelresponsiblemonogenicandoligogenicvariants
AT qinyingying nextgenerationsequencingof500poipatientsidentifiednovelresponsiblemonogenicandoligogenicvariants